{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comparator%3A+Placebo&page=2",
    "query": {
      "intervention": "Comparator: Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comparator%3A+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T03:22:37.859Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00509106",
      "title": "Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil for Injection",
          "type": "DRUG"
        },
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 622,
      "start_date": "2007-07",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-14",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509106"
    },
    {
      "nct_id": "NCT04659278",
      "title": "Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Alcohol Use, Unspecified",
        "Alcohol Abstinence",
        "Alcohol-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Endourage 1200 mg OMD ™ Oral Mucosal Drops",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Isolate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Peppermint Oil, masking flavor",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Endourage, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-09",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 1,
      "location_summary": "Novato, California",
      "locations": [
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04659278"
    },
    {
      "nct_id": "NCT00360555",
      "title": "Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sexual Dysfunctions, Psychological"
      ],
      "interventions": [
        {
          "name": "flibanserin",
          "type": "DRUG"
        },
        {
          "name": "flibanserin 50mg",
          "type": "DRUG"
        },
        {
          "name": "flibanserin 100mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sprout Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 1584,
      "start_date": "2006-07",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360555"
    },
    {
      "nct_id": "NCT00609115",
      "title": "Sub-Acute Stroke Rehabilitation With AMES",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cerebrovascular Stroke"
      ],
      "interventions": [
        {
          "name": "AMES device (test)",
          "type": "DEVICE"
        },
        {
          "name": "AMES device (sham)",
          "type": "DEVICE"
        },
        {
          "name": "AMES device (crossover)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AMES Technology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 83,
      "start_date": "2007-09-01",
      "completion_date": "2011-02-28",
      "has_results": true,
      "last_update_posted_date": "2022-10-03",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 5,
      "location_summary": "Rancho Mirage, California • San Francisco, California • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00609115"
    },
    {
      "nct_id": "NCT01537068",
      "title": "Desvenlafaxine vs. Placebo Treatment of Chronic Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dysthymic Disorder",
        "Dysthymia",
        "Chronic Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Desvenlafaxine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2012-02",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537068"
    },
    {
      "nct_id": "NCT01821378",
      "title": "Lurasidone Low-Dose - High-Dose Study Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Lurasidone",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 412,
      "start_date": "2013-05",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-07-21",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 28,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Escondido, California + 22 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821378"
    },
    {
      "nct_id": "NCT00362115",
      "title": "Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Azilsartan Medoxomil",
          "type": "DRUG"
        },
        {
          "name": "Olmesartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 449,
      "start_date": "2006-05",
      "completion_date": "2006-12",
      "has_results": true,
      "last_update_posted_date": "2011-04-19",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 46,
      "location_summary": "Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362115"
    },
    {
      "nct_id": "NCT00998218",
      "title": "Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sudden Cardiac Death",
        "Ventricular Arrythmias"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aspirus Heart and Vascular Institute-Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2009-09",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-09",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 1,
      "location_summary": "Wausau, Wisconsin",
      "locations": [
        {
          "city": "Wausau",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998218"
    },
    {
      "nct_id": "NCT00557921",
      "title": "Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome",
        "Myocardial Infarction",
        "Coronary Artery Disease",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin",
          "type": "DRUG"
        },
        {
          "name": "Plavix (clopidogrel 75 mg) and aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogentus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2007-12",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2009-01-28",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 247,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00557921"
    },
    {
      "nct_id": "NCT00843713",
      "title": "Effect of Raltegravir on Endothelial Function in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection",
        "Inflammation",
        "Cardiovascular Disease",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2009-01",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-09-27T03:22:37.859Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00843713"
    }
  ]
}